Ardent Health Faces Class Action for Securities Fraud
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy ARDT?
Source: Globenewswire
- Lawsuit Background: Bleichmar Fonti & Auld LLP has filed a class action against Ardent Health and its executives for securities fraud, resulting in a significant 33% stock drop on November 13, 2025.
- Financial Misrepresentation: The lawsuit alleges that Ardent Health delayed recognizing uncollectible accounts, leading to inflated accounts receivable figures during the reporting period, which misled investors.
- Stock Price Impact: On November 12, 2025, Ardent Health revealed a $43 million revenue decrease due to historical collection evaluations and increased professional liability reserves by $54 million, causing its stock price to plummet from $14.05 to $9.30.
- Legal Consequences: Investors have until March 9, 2026, to apply to lead the case, which is pending in the U.S. District Court for the Middle District of Tennessee, potentially impacting Ardent Health's future operations and financial health.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARDT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARDT
Wall Street analysts forecast ARDT stock price to rise
13 Analyst Rating
8 Buy
4 Hold
1 Sell
Moderate Buy
Current: 9.480
Low
10.00
Averages
13.73
High
17.00
Current: 9.480
Low
10.00
Averages
13.73
High
17.00
About ARDT
Ardent Health, Inc., formerly Ardent Health Partners, Inc., is a provider of healthcare in mid-sized urban communities across the United States. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and approximately 280 sites of care with over 1,800 affiliated providers across six states. It provides both general and specialty services, including internal medicine, general surgery, cardiology, oncology, orthopedics, women’s services, neurology, urology, and emergency services, within inpatient and ambulatory care settings. In addition to its 30 acute care hospitals, it operates a network of ambulatory facilities and telehealth services, including primary care and specialty care clinics, ambulatory surgery centers (ASCs), urgent care centers, free-standing emergency departments, and diagnostic imaging centers. It operates a consumer-centric healthcare platform focused on creating relationships with its patients across multiple care settings.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Lawsuit Background: Bleichmar Fonti & Auld LLP has filed a class action against Ardent Health and its executives for securities fraud, resulting in a significant 33% stock drop on November 13, 2025.
- Financial Misrepresentation: The lawsuit alleges that Ardent Health delayed recognizing uncollectible accounts, leading to inflated accounts receivable figures during the reporting period, which misled investors.
- Stock Price Impact: On November 12, 2025, Ardent Health revealed a $43 million revenue decrease due to historical collection evaluations and increased professional liability reserves by $54 million, causing its stock price to plummet from $14.05 to $9.30.
- Legal Consequences: Investors have until March 9, 2026, to apply to lead the case, which is pending in the U.S. District Court for the Middle District of Tennessee, potentially impacting Ardent Health's future operations and financial health.
See More
- Lawsuit Notification: Kahn Swick & Foti reminds investors who purchased Ardent Health securities between July 18, 2024, and November 12, 2025, to file lead plaintiff applications by March 9, 2026, to participate in the ongoing class action lawsuit against the company.
- Financial Disclosure Issues: On November 12, 2025, Ardent disclosed a $43 million decrease in Q3 revenue due to a transition to a new revenue accounting system and evaluations of historical collection trends, resulting in a nearly 34% drop in share price the following day.
- Earnings Guidance Cut: The company lowered its 2025 EBITDA guidance to between $530 million and $555 million, down approximately 9.6% from the previous range of $575 million to $625 million, reflecting intensified industry cost pressures and payer denials.
- Increased Legal Liabilities: Ardent recorded a $54 million increase in professional liability reserves related to settlements and ongoing litigation from 2019 to 2022 in New Mexico, indicating heightened legal risks and potential financial burdens for the company.
See More
- Class Action Notice: Rosen Law Firm reminds investors who purchased Ardent Health securities between July 18, 2024, and November 12, 2025, to apply as lead plaintiffs by March 9, 2026, to participate in the class action without any out-of-pocket fees.
- False Representation Allegations: The lawsuit alleges that Ardent Health made false representations regarding its accounts receivable, claiming to use 'detailed historical collections reviews' for collectability assessments, which misled investors and resulted in financial losses.
- Insurance Shortfall Issues: Ardent Health failed to maintain sufficient professional malpractice liability insurance to cover potential claims arising from operations, particularly facing significant social inflationary pressures in medical malpractice cases in New Mexico, impacting the company's financial stability.
- Legal Counsel Selection Advice: Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record, as many firms issuing notices lack the capability to handle securities class actions, urging investors to choose their representatives wisely.
See More
- Lawsuit Background: Rosen Law Firm reminds investors of a class action lawsuit for purchasers of Ardent Health, Inc. (NYSE: ARDT) securities between July 18, 2024, and November 12, 2025, alleging misleading statements about the company's operations that may have led to investor losses.
- False Statement Allegations: The lawsuit claims that Ardent Health misrepresented its accounts receivable monitoring process, stating it relied on 'detailed reviews of historical collections,' which was not the case, resulting in inflated accounts receivable figures in financial reports.
- Insurance Shortfall Issues: Ardent Health is accused of failing to maintain adequate professional malpractice liability insurance to cover potential claims arising from operations, particularly in the New Mexico market where social inflationary pressures in malpractice cases have been increasing, potentially jeopardizing the company's financial stability.
- Investor Losses: As the true details emerged, investors faced damages, and Rosen Law Firm encourages affected shareholders to file motions to serve as lead plaintiffs by March 9, 2026, to represent other shareholders in the litigation.
See More
- Lawsuit Background: Ardent Health is facing a securities class action lawsuit for allegedly failing to disclose its accounts receivable accounting practices, with plaintiffs claiming the use of a 180-day reserve period delayed loss recognition, resulting in a nearly 34% stock price drop in November 2025.
- Financial Impact: In November 2025, Ardent was forced to slash revenue by $42.6 million to reflect the impact of its new accounting method, triggering strong investor backlash and exacerbating concerns over its financial transparency.
- Liability Reserves Surge: The company recorded a $54 million increase in professional liability reserves during the same period, primarily due to settlements and ongoing litigation in New Mexico from 2019 to 2022, which not only affected its financial standing but could also impact future insurance costs and risk management strategies.
- Investor Action: Hagens Berman has notified investors that the lead plaintiff deadline is March 9, 2026, encouraging those who purchased Ardent shares between July 18, 2024, and November 12, 2025, to participate in the lawsuit for potential compensation.
See More
- Litigation Investigation: Faruq & Faruq LLP is investigating potential securities claims against Ardent Health, urging investors to apply by April 21, 2026, to become lead plaintiffs in a federal class action, indicating significant legal risks that could impact stock performance.
- Financial Loss Disclosure: Ardent Health revealed a $43 million decrease in Q3 2025 revenue on November 12, 2025, primarily due to revised assessments of accounts receivable collectability from a new revenue accounting system, highlighting insufficient financial transparency that may erode investor confidence.
- EBITDA Guidance Cut: The company lowered its 2025 EBITDA guidance to $530 million to $555 million, down approximately 9.6% from the previous range of $575 million to $625 million, reflecting increased industry-wide cost pressures that could affect future profitability.
- Stock Price Volatility: Following the negative financial news, Ardent Health's stock plummeted by $4.75, nearly 34%, from $14.05 to $9.30 per share on November 13, 2025, indicating extreme market pessimism regarding the company's outlook.
See More








